找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Cancer Immunotherapies; Solid Tumors and Hem Priya Hays Book 2022 The Editor(s) (if applicable) and The Author(s), under exclusive license

[复制链接]
查看: 47658|回复: 49
发表于 2025-3-21 20:07:59 | 显示全部楼层 |阅读模式
书目名称Cancer Immunotherapies
副标题Solid Tumors and Hem
编辑Priya Hays
视频videohttp://file.papertrans.cn/222/221136/221136.mp4
概述Presents the clinical scope of cancer immunotherapeutic agents for solid tumors and hematological malignancies.Examines the latest advances and their implications for clinical practice.Written and edi
丛书名称Cancer Treatment and Research
图书封面Titlebook: Cancer Immunotherapies; Solid Tumors and Hem Priya Hays Book 2022 The Editor(s) (if applicable) and The Author(s), under exclusive license
描述.This book presents the clinical scope of cancer immunotherapeutic agents for solid tumors and Hematologic malignancies, elaborates on the scientific details of their modes of action, and presents the impact of these agents on oncology, patients and the broader healthcare system. At present, cancer immunotherapies fall broadly into three categories: immune checkpoint inhibitors (ICIs), adoptive T cell therapies, and cancer vaccines which have distinct mechanisms of action. Immune checkpoint inhibitors rely upon disrupting tumor antigen recognition as self by the immune system through inhibition of checkpoint molecules. Adoptive T cell therapies involve the engineering of T cells ex vivo to target and destroy tumor cells..The first part of this book will provide an overview of the discovery and mechanistic details of the technology. The second part will be devoted to elaborating on the clinical outcomes, successes and limitations for specific tumor subtypes, which includes bothsolid tumors and hematologic malignances for both pediatric and adult populations. As such, the book offers a valuable resource for oncologists, hematologists, and all those seeking an up-to-date overview of c
出版日期Book 2022
关键词Cancer Immunotherapy; hematological malignancies; immune checkpoint inhibitors; adoptive T cell therapi
版次1
doihttps://doi.org/10.1007/978-3-030-96376-7
isbn_softcover978-3-030-96378-1
isbn_ebook978-3-030-96376-7Series ISSN 0927-3042 Series E-ISSN 2509-8497
issn_series 0927-3042
copyrightThe Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerl
The information of publication is updating

书目名称Cancer Immunotherapies影响因子(影响力)




书目名称Cancer Immunotherapies影响因子(影响力)学科排名




书目名称Cancer Immunotherapies网络公开度




书目名称Cancer Immunotherapies网络公开度学科排名




书目名称Cancer Immunotherapies被引频次




书目名称Cancer Immunotherapies被引频次学科排名




书目名称Cancer Immunotherapies年度引用




书目名称Cancer Immunotherapies年度引用学科排名




书目名称Cancer Immunotherapies读者反馈




书目名称Cancer Immunotherapies读者反馈学科排名




单选投票, 共有 1 人参与投票
 

0票 0.00%

Perfect with Aesthetics

 

0票 0.00%

Better Implies Difficulty

 

1票 100.00%

Good and Satisfactory

 

0票 0.00%

Adverse Performance

 

0票 0.00%

Disdainful Garbage

您所在的用户组没有投票权限
发表于 2025-3-21 21:18:16 | 显示全部楼层
发表于 2025-3-22 03:22:36 | 显示全部楼层
发表于 2025-3-22 07:15:22 | 显示全部楼层
Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma,efficacy and safety of CAR T cell therapy in GBM. In this review, common challenges associated with treating GBM will be discussed in addition to how CAR T cells can overcome such barriers. Additionally, emerging techniques of optimizing CAR T cell therapy for GBM will be emphasized, highlighting the prospective promise of cellular immunotherapy.
发表于 2025-3-22 10:11:33 | 显示全部楼层
发表于 2025-3-22 14:14:34 | 显示全部楼层
发表于 2025-3-22 19:48:02 | 显示全部楼层
发表于 2025-3-22 22:46:33 | 显示全部楼层
发表于 2025-3-23 03:57:47 | 显示全部楼层
Engaging Pattern Recognition Receptors in Solid Tumors to Generate Systemic Antitumor Immunity,rticularly with the goal of generating Th1-promoting inflammation that stokes endogenous priming of antitumor CD8. T cells, is a growing area of clinical investigation. This approach is analogous to in situ vaccination, ultimately providing a personalized antitumor response against relevant tumor as
发表于 2025-3-23 05:47:12 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 吾爱论文网 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
QQ|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-8-25 14:37
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表